AG Rosenwald
Molecular genesis of malignant lymphomas
Our research group focuses on investigating the molecular causes of malignant B- and T-cell lymphomas as well as multiple myeloma. Advanced genetic analyses, gene expression measurements, and modern sequencing techniques are employed. In recent years, a key focus has been on the molecular study of biologically and clinically relevant lymphoma subtypes, such as diffuse large B-cell lymphomas. The group is also actively exploring the cellular composition of the microenvironment in aggressive lymphomas and drug resistance in mantle cell lymphoma.
The research group plays a central role in several national and international research networks, including the "Leukemia and Lymphoma Molecular Profiling Project" (LLMPP) of the National Cancer Institute (USA), the National Center for Tumor Diseases (NCT)-WERA, the BMBF-funded project "Federated Learning in Lymphoma Pathology," as well as the German Lymphoma Alliance registry study MMML-Predict, which is funded by the Deutsche Krebshilfe. The researchers of our group are also active members of the European MCL Network, the Competence Network Malignant Lymphomas (KML) and the International Lymphoma Study Group (ILSG).
Prof. Rosenwald and PD Dr. Hilka Rauert-Wunderlich are involved in several lectures, seminars and courses of the medical faculty.
Prof. Dr. Andreas Rosenwald
PD Dr. Hilka Rauert-Wunderlich
Tina Grieb
Theodora Nedeva
Glaser S, Fischer A, Martinez-Manjon JE, Lopez C, Kretzmer H, Burkhardt B, Hubschmann D, Hummel M, Klapper W, Kolarova J, Kreuz M, Ott G, Radlwimmer B, Rosolowski M, Schlesner M, Rosenwald A, Stilgenbauer S, Wagener R, Zwir I, Trumper L, Kuppers R, Lichter P, Ammerpohl O, Del Val C, Siebert R, consortium IM-S. Subgrouping germinal center-derived B-cell lymphomas based on machine learning-deduced DNA methylation modules. Leukemia. 2025;doi:10.1038/s41375-025-02533-6.
Krebs M, Haller F, Sporl S, Gerhard-Hartmann E, Utpatel K, Maurus K, Kunzmann V, Chatterjee M, Venkataramani V, Maatouk I, Bittrich M, Einwag T, Meidenbauer N, Togel L, Hirsch D, Dietmaier W, Keil F, Scheiter A, Immel A, Heudobler D, Einhell S, Kaiser U, Sedlmeier AM, Maurer J, Schenkirsch G, Jordan F, Schmutz M, Dintner S, Rosenwald A, Hartmann A, Evert M, Markl B, Bargou R, Mackensen A, Beckmann MW, Pukrop T, Herr W, Einsele H, Trepel M, Goebeler ME, Claus R, Kerscher A, Luke F. The WERA cancer center matrix: Strategic management of patient access to precision oncology in a large and mostly rural area of Germany. Eur J Cancer. 2024;207:114144;doi:10.1016/j.ejca.2024.114144.
Fuhr V, Heidenreich S, Srivastava M, Riedel A, Dull J, Gerhard-Hartmann E, Rosenwald A, Rauert-Wunderlich H. CD52 and OXPHOS-potential targets in ibrutinib-treated mantle cell lymphoma. Cell Death Discov. 2022;8(1):505;doi:10.1038/s41420-022-01289-7.
Zamo A, Gerhard-Hartmann E, Ott G, Anagnostopoulos I, Scott DW, Rosenwald A, Rauert-Wunderlich H. Routine application of the Lymph2Cx assay for the subclassification of aggressive B-cell lymphoma: report of a prospective real-world series. Virchows Arch. 2022;481(6):935-43;doi:10.1007/s00428-022-03420-6.
